市場調査レポート

商品コード

1544183

血液スクリーニングの市場規模、シェア、成長分析：製品・サービス別、技術別、エンドユーザー別、地域別 - 産業予測、2024-2031年

Blood Screening Market Size, Share, Growth Analysis, By Product Type (Reagents & Kits, Instruments), By Technology (Nucleic Acid Test (NAT), Rapid Tests), By End User (Hospitals & Clinics, Diagnostic Centers), By Region - Industry Forecast 2024-2031

出版日: 2024年08月24日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

血液スクリーニングの世界市場規模は、2022年に30億4,000万米ドルと評価され、2023年の33億米ドルから2031年には63億3,000万米ドルに達し、予測期間中（2024-2031年）のCAGRで8.50%の成長が予測されています。

血液スクリーニング用の自動分子プラットフォームは、業界をリードする企業がこの技術を採用することで、市場の大きな成長を牽引しています。この市場拡大の主な要因としては、献血者数と献血者数の増加、血液の安全性に対する意識の高まり、感染症の罹患率の上昇、政府のさまざまな取り組みなどが挙げられます。また、主要な手術、特に小児貧血、外傷、先天性血液疾患の管理に不可欠な輸血の頻度も、市場の利益となっています。当社の分析によると、世界では毎年2億3,400万件以上の大手術が行われており、頻繁な輸血が必要とされています。また、世界中で約1億1,850万件の献血が行われており、その40％は高所得国からのもので、世界の献血量の16％を占めています。献血の分布は所得レベルによって異なり、高所得国が31.5％、高中所得国が15.9％、低中所得国が6.8％、低所得国が5.0％を占めています。診断検査情勢は、主要業界企業間の戦略的パートナーシップに牽引され、大幅な成長を遂げようとしています。これらの提携により、高度な診断検査の利用可能性が高まると期待されています。例えば、2023年3月、TruDiagnostic社は、NAD診断を専門とするフィンランドのNADMED社と提携し、革新的なNAD+血液診断検査を米国で発売しました。この提携は、診断能力の拡大と市場成長に向けた傾向の高まりを浮き彫りにしています。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Abbott Laboratories（USA）
Becton, Dickinson and Company（USA）
Bio-Rad Laboratories, Inc.（USA）
bioMerieux SA（France）
F. Hoffmann-La Roche Ltd.（Switzerland）
Grifols, S.A.（Spain）
Hologic, Inc.（USA）
Immucor, Inc.（USA）
Meridian Bioscience, Inc.（USA）
Ortho Clinical Diagnostics（USA）
Quotient Limited（UK）
Siemens Healthineers AG（Germany）
Sysmex Corporation（Japan）
Thermo Fisher Scientific Inc.（USA）
Danaher Corporation（USA）
Grifols Diagnostic Solutions Inc.（USA）
Haemonetics Corporation（USA）
Luminex Corporation（USA）
Natera, Inc.（USA）
Novartis International AG（Switzerland）
PerkinElmer, Inc.（USA）
Promega Corporation（USA）

Product Code: SQMIG35J2044

Global Blood Screening Market size was valued at USD 3.04 Billion in 2022 and is poised to grow from USD 3.30 Billion in 2023 to USD 6.33 Billion by 2031, at a CAGR of 8.50% during the forecast period (2024-2031).

Automated molecular platforms for blood screening are driving significant growth in the market, as leading industry players adopt this technology. Key factors fueling this expansion include the increasing number of blood donations and donors, heightened awareness of blood safety, the rising incidence of infectious diseases, and various government initiatives. The market is also benefiting from the frequency of blood transfusions, which are essential in major surgeries, particularly in managing childhood anemia, trauma, and congenital blood disorders. Based on our analysis, over 234 million major surgeries are conducted globally each year, necessitating frequent blood transfusions. Our study also reveals that approximately 118.5 million blood donations occur worldwide, with 40% coming from high-income countries, which contribute to 16% of global donations. The distribution of donations varies by income level, with high-income countries accounting for 31.5% of donations, upper-middle-income countries 15.9%, lower-middle-income countries 6.8%, and low-income countries 5.0%. The diagnostic testing landscape is poised for substantial growth, driven by strategic partnerships among key industry players. These collaborations are expected to enhance the availability of advanced diagnostic tests. For instance, in March 2023, TruDiagnostic partnered with NADMED, a Finnish company specializing in NAD diagnostics, to launch an innovative NAD+ blood diagnostic test in the U.S. This partnership highlights the increasing trend towards expanding diagnostic capabilities and market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Blood Screening market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Blood Screening Market Segmental Analysis

Global Blood Screening Market is segmented based on product type, technology, end users, and region. Based on product & service, the market is segmented into Reagents & Kits [NAT Reagents & Kits, ELISA Reagents & Kits, Other Reagents & Kits], Instruments [Rental Purchase, Outright Purchase], Software & Services. Based on technology, the market is segmented into Nucleic Acid Test (NAT) [Transcription-mediated Amplification (TMA), Real-time Polymerase Chain Reaction (RT-PCR)], Serology/Immunoassay [Chemiluminescent Immunoassays (CLIA), Fluorescent Immunoassays (FIA), Colorimetric Immunoassays/ELISA (CI/ELISA)], Rapid Tests, Western Blot Assays, Next-generation Sequencing (NGS). Based on end user, the market is segmented into hospitals & clinics, diagnostic centres, and blood banks. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Blood Screening Market

Awareness among healthcare professionals and patients regarding the risks of blood transfusions, such as the transmission of infectious diseases, is increasing. This heightened awareness is driving a greater demand for blood screening products that ensure the safety of blood and blood products. Additionally, the growing prevalence of blood-related disorders and the rising need for blood and blood products for various medical procedures, including transfusions and surgeries, are contributing to the expansion of the blood screening market. This demand underscores the need for effective screening solutions to enhance safety and manage the risks associated with blood transfusions.

Restraints in the Global Blood Screening Market

The shortage of phlebotomists, laboratory technicians, and other skilled professionals could hinder the widespread adoption of blood screening products. Healthcare organizations and blood banks may face difficulties in finding qualified personnel to operate the equipment and conduct the tests, potentially limiting their ability to implement blood screening programs effectively. This workforce gap poses a significant challenge to expanding the use of blood screening technologies and ensuring their widespread availability.

Market Trends of the Global Blood Screening Market

The rising demand for plasma-derived products, including immunoglobulins and clotting factors, is significantly boosting the need for blood screening products that ensure the safety of these essential therapies. As plasma-derived treatments continue to expand into new therapeutic areas, the demand for reliable blood screening solutions is expected to grow. In the United States, the increasing prevalence of chronic diseases such as cancer, diabetes, and thyroid disorders is anticipated to further drive market growth. The American Cancer Society's "Cancer Facts and Figures 2023" report projects around 1.9 million new cancer cases for the year, with prostate cancer being the most common, followed by lung and female breast cancers. Similarly, data from the Government of Canada reported 233,900 new cancer diagnoses, with prostate cancer remaining the most prevalent. This rising cancer burden is likely to boost the demand for blood testing services, supporting market expansion throughout the forecast period.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors of The Market
Degree Of Competition
Top Investment Pockets
Market Attractive Index
Ecosystem Mapping
Patent Analysis
Pricing Analysis
Trade Analysis
Consumer And Buying Criteria
Regulatory Analysis
Technology Analysis
Case study Analysis

Global Blood Screening Market by Product and services

Market Overview
Reagents and kits
- NAT reagents and kits
- Elisa reagents and kits
- Other Reagents and kits
Instruments
- Rental purchase
- Outright purchase
Software and services

Global Blood Screening Market by Technology

Market Overview
Nucleic acid test
- Transcription-mediated Amplification
- Real-time PCR
Serology/Immunoassay
- Chemiluminescent Immunoassays
- Fluorescent Immunoassays
- Colorimetric Immunoassays/ELISA
Rapid Tests
Western Blot Assays
Next-generation Sequencing

Global Blood Screening Market by End-user

Market Overview
Hospitals & Clinics
Diagnostic centers
Blood Banks

Global Blood Screening Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Immucor, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Meridian Bioscience, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ortho Clinical Diagnostics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quotient Limited (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols Diagnostic Solutions Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Haemonetics Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Luminex Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Promega Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

血液スクリーニングの市場規模、シェア、成長分析：製品・サービス別、技術別、エンドユーザー別、地域別 - 産業予測、2024-2031年

Blood Screening Market Size, Share, Growth Analysis, By Product Type (Reagents & Kits, Instruments), By Technology (Nucleic Acid Test (NAT), Rapid Tests), By End User (Hospitals & Clinics, Diagnostic Centers), By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

血液スクリーニング市場：製品・サービス別

血液スクリーニング市場：技術別

血液スクリーニング市場：エンドユーザー別

血液スクリーニング市場規模：地域別